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Summary All-trans retinoic acid (RA) was previously shown to regulate the growth of gastric cancer cells derived from the cell line SC-Mi.
This study was designed to investigate the effect of RA on the sensitivity of SC-Mi cells to lymphokine-activated killer (LAK) activity. RA at the
concentration range of 0.001-10 kM was shown to induce SC-Mi cells to exhibit resistance to LAK activity in a dose-dependent manner.
A kinetics study indicated that a significantly increased resistance was detected after 2 days of co-culturing SC-Mi cells with RA and reached
a maximum after 6 days of culture. Similar results were obtained from two other cancer cell lines: promyelocytic leukaemia HL-60 and hepatic
cancer Hep 3B. A binding assay demonstrated that the binding efficacy between target SC-M1 cells and effector LAK cells was not altered by
RA. Flow cytometric analyses revealed that RA exhibited no effect on the expression of cell surface molecules, including HLA class and
class 11 antigens, intercellular adhesion molecule-1 and -2, and lymphocyte function antigen-3. Cell cycle analysis revealed that culture of
SC-Mi cells with RA resulted in an increase in GJG, phase and a decrease in S phase, accompanied by a decrease in cyclin A and cyclin Bi
mRNA as determined by Northern blot analysis. Additionally, RA was shown to enhance the expression of retinoic acid receptor a (RARa) in
SC-Mi cells, and to have no effect on the expression of RARfi or RARy. Taken together, these results indicate that RA can significantly
increase gastric cancer cells SC-Mi to resist LAK cytotoxicity by means of a cytostatic effect through a mechanism relating to cell cycle
regulation. The prevailing ideas, such as a decrease in effector to target cell binding, a reduced MHC class antigen expression or an altered
RARP expression, are not involved.
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Differentiation induction is a new treatment modality for cancer
(Dmitrovsky et al, 1990; Degos, 1992). Retinoids are well-known
differentiation-enhancing agents and have been shown to exert anti-
neoplastic activities in vitro against a variety of cancers, including
acute promyelocytic leukaemia, germ cell tumours, breast cancer,
head and neck squamous cell carcinoma, myeloma and neuroblas-
toma (Strickland and Sawey, 1980; Butler and Fontana, 1992; Zou
et al, 1994; Cohen et al, 1995; Palumbo et al, 1995). Furthermore,
all-trans retinoic acid (RA) has been usedeffectively in vivo to treat
acute promyelocytic leukaemia patients (Huang et al, 1988; Degos,
1992; Warrell et al, 1991, 1993). Recently, our laboratory demon-
strated that RA regulated the growth of a gastric cancer cell line,
SC-MI, and induced morphological changes (Shyu et al, 1995),
suggesting that RA is also of potential in the treatment of gastric
cancerby differentiation induction.
Retinoic acid has been shown to modulate immunological func-
tions by a variety of mechanisms, including the enhancement of
antibody response to antigens, T-lymphocyte-mediated immune
response, phagocytosis by macrophages, lymphokine-activated
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killer (LAK) activity and natural killer cell activity
(Athanassiades, 1981; Dillehay et al, 1988; Lin and Chu, 1990;
Villa et al, 1993; Fegan et al, 1995). Therefore, combined use of
RA with cytokines, such as interleukin 2 (IL-2), has been consid-
ered in anti-cancer treatment (Bollag and Peck, 1993). Yet the
exact mechanisms underlying the effectiveness of RA, especially
its direct action on tumour cells, remain unclear. Retinoic acid
binds to and induces the expression of retinoic acid receptors
(RARs) and retinoid x receptors (RXRs), which activate gene
expression to initiate the mechanisms that control cellular differ-
entiation and cell growth (Love and Gudas, 1994). Treatment of
cancer cells with RA is frequently accompanied by alterations of
tumour cell surface proteins, including intercellular adhesion
molecule (ICAM) (Triozzi et al, 1992; Bouillon and Audette,
1994). These cell surface alterations may result in a change ofthe
binding of immune effector cells, including LAK cells, to target
cancer cells, and consequently may lead to an increase or a
decrease in the susceptibility to cell-mediated cytotoxicity.
This study was designed to investigate the effect ofRA, ifany, on
the sensitivity of gastric cancer cells SC-Mi to LAK activity, with
the goal of determining in vitro whether RA and IL-2 or LAK cells
are effective for combination biological therapy. The results revealed
that RA decreased the susceptibility of gastric cancer
SC-Mi cells to LAK lysis. The underlying mechanism was in part
caused by the effect of RA on cell cycle regulation, and the
prevailing notions, such as thebinding ofeffectorcells to targetcells,
the expression of ICAM molecules or major histocompatibility
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complex (MHC) class I molecules and the alteration ofRARP, are
not involved. These results may also advise caution as to the suit-
ability ofRA with LAK cells or IL-2 biotherapy in certain cancers,
especially in the light of the most recent report describing the
combination of ,-carotene and vitamin A as having no benefit and
possibly an adverse effect on lung cancer (Omenn et al, 1996).
MATERIALS AND METHODS
Target cells
Three cancer cell lines, including gastric cancer SC-MI, promye-
locytic leukaemia HL-60 and hepatic cancer Hep 3B, were used as
target cells in the cytotoxicity assay. Tumour cells were main-
tained in RPMI-1640 medium with 10% fetal calf serum (FCS)
(Gibco, Grand Island, NY, USA).
Recombinant IL-2
IL-2 was kindly provided by Cetus Oncology Corperation
(Emeryville, CA, USA).
Generation of LAK killer cell activity
LAK cell activity was generated as described previously (Chao et
al, 1990, 1995a). Briefly, peripheral blood mononuclear cells
(PBMCs) were obtained from normal healthy volunteers and incu-
bated at 37°C in complete medium containing 3000 IU ml-' IL-2,
under a moist atmosphere with 5% carbon dioxide in culture flasks
at a cell concentration of 2-3 x 106 ml'. Complete medium
contained RPMI-1640 with 10% FCS, 0.3 mg ml-1 L-glutamine,
100 gg ml-' streptomycin and 100 U ml-' penicillin. Activated
killer cells were harvested after culture for 4 days and washed
twice with RPMI-1640. The viable cells were counted and resus-
pended in RPMI-1640 containing 10% FCS for the standard
4-h 5'Cr-release assay (Chao et al, 1990, 1995a), and for surface
marker studies with flow cytometry (Chao et al, 1995b).
Co-culturing cancer cells with RA
RA (j-all-trans, Sigma, St Louis, MO, USA) was dissolved in a
small amount of dimethyl sulphoxide (Sigma) to make a stock
solution of0.01 M. This solution was used at a final concentration
ranging from 0.001-10 gM in complete medium. RA was added to
the culture medium at the beginning of the culture. After incuba-
tion for various periods of time, tumour cells were harvested,
washed and used as target cells in the standard 4-h 51Cr-release
assay. Preliminary experiments showed dimethyl sulphoxide alone
at the concentrations used had no effect on the susceptibility of
cancer cells to LAK cytotoxicity.
In vitro cytotoxicity assay
The standard 4-h 5'Cr-release microcytotoxicity assay was
performed as described (Chao et al, 1990, 1995a). Each cytotoxi-
city assay was performed in triplicate and the results were
expressed as lytic units. To ensure the validity of the assay data,
the maximum spontaneous release of 51Cr of target cells in this
study was limited to 12%. There was no spontaneous cytotoxicity
of RA on SC-MI cells in our experiments. One lytic unit was
defined as the number of effector cells required to cause 30%
specific 5"Cr release from 104 target cells and was expressed as
lytic unit 10-7 effector cells.
Flow cytometric analysis of cell surface molecules on
SC-Mi cells
Cell surface molecules on SC-Mi cells were examined by flow
cytometry after immunofluorescence staining. Tumour cells
cultured for 6 days, in the presence or absence of RA, were
harvested, washed twice and resuspended in RPMI-1640. The cell
concentrations were adjusted to 1 x 106 ml-' and incubated with
mouse anti-human monoclonal antibodies against HLA class I
and II antigens (Dako, Carpinteria, CA, USA), ICAM-1 and
-2 (Bender, Vienna, Austria) or lymphocyte function antigen-3
(LFA-3) (Serotec, Oxford, UK), for 30 min at 4°C and then
washed with phosphate-buffered saline (PBS) three times. These
cells were then incubated with goat anti-mouse antibodies conju-
gated with fluorescein isothiocyanate for 30 min at 4°C. After
three washes in PBS containing 0.05% Tween 20, cells stained in
indirect immunofluorescence were resuspended in 200 gl of
sheath fluid without azide and analysed in a flow cytometer
(FACScan, Becton-Dickinson).
Cell cycle analysis
Cell cycle analysis was performed by using flow cytometry as
previously described (Shyu et al, 1995). Briefly, cells in loga-
rithmic growth were labelled with 5 mmbromodeoxyuridine for20
min. Cells were then harvested and fixed in 70% ethanol. Nuclei
were prepared by incubating cells in 0.04% pepsin, 0.1 N
hydrochloric acid for 20 min at room temperature, followed by
the addition of 2 N hydrochloric acid at 37°C for 30 min.
Following neutralization with 0.1 M sodium borate, nuclei were
stained with anti-bromodeoxyuridine monoclonal antibody
(Becton-Dickinson) at room temperature for 30 min and fluores-
cein-labelled goat anti-mouse antibody (1:50) (Sigma) for 30 min.
Nuclei were then stained with 10 gg ml-' propidium iodide, 5 mg
ml-' RNAase overnight at 4°C and analysed by FACScan. The
fractions ofcells inGO/GI, S and G2/M phases were analysed using
the LYSYS program.
Binding assay
Target cells (1 x 105) and LAK cells (5 x 105) are mixed in 0.2 ml
ofcomplete medium in anEppendorftube and incubated for 5 min
at 37°C in a humidified 5% carbon dioxide atmosphere. The tubes
were then centrifuged for 30 s, after which the pellet was pipetted
gently three times and resuspended and incubated for another
5 min at 37°C in a humidified 5% carbon dioxide atmosphere. The
percentage binding of effector cells to target cells was determined
by counting at least 200 target cells.
RNA preparation and Northern blot analysis
Poly (A)+ RNA preparation and Northern blot analysis were
performed as previously described (Shyu et al, 1995). Cells were
lysed in buffer containing 0.2 M sodium chloride, 0.2 M Tris-HCl,
pH 7.5, 1.5 mm magnesium chloride, 2% sodium dodecyl sulphate
(SDS), 200 gg ml-' protease K and 50 ,UM aurintricarboxylic acid
and incubated at 45°C for 2 h. Cell lysates were then incubated
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with oligo-dT cellulose (Boehringer Mannhiem) in the same buffer
containing 0.5 M sodium chloride at room temperature for 1 h on
a rotary shaker. After washing, RNA was eluted with 0.01 M
Tris-HCl, pH 7.5. RNA was then fractionated on a 1.1% agarose,
1.1% formaldehyde gel in 5 mm NaOAc, 1 mm EDTA, 20 mm
3-[N-morpholino] propanesulphonic acid, pH 7.0, and transferred
to a nylon membrane by capillary blotting in 20 x saline sodium
citrate (SSC) (3 M sodium chloride, 0.3 M sodium citrate, pH 7.0).
Blots were UV-fixed prehybridized and hybridized at 42°C in
buffer containing 50% (v/v) formamide, 5 x SSC, 2% (w/v)
blocking reagent, 0.1% N-lauroylsarcosine and 0.2 (w/v) SDS. The
membranes were washed with 2 x SSC containing 0.1% SDS and
then washed with 0.1 x SSC containing 0.1% SDS at 68°C for
30 min. Specific hybridization was detected by a DIG luminescent
detection kit using lumigen-PPD as the substrate and was recorded
using Kodak XAR-5 film at room temperature. To prepare
membranes for rehybridization, membranes were incubated with
0.5% Tris-HCl, pH 8.0, 1% SDS and 50% formamide at 68°C for
1 h and then prehybridized as described above.
cDNA probes encoding Drosophila actin, mouse RARoc, human
RARP and human RARy were prepared as previously described
(Shyu et al, 1995). The 1.7-kb cyclin A cDNA probe and the 1.4-kb
cyclin B cDNA probe were kindly provided by Dr C Brechet and
Dr T Hunter. The 1.25-kb GAPDH cDNA was provided by Dr R
Wu. cDNAs were labelled with digoxigenin using a DNA labelling
kit. The relative levels of RARa (3.5 and 2.9 kb), RARP (3.4 and
3.1 kb) and RARy(3.2 and 3.0 kb) were normalized to the level of
3-actin mRNA from the same nylon membrane. Normalizations of
the levels of cyclin A and cyclin B1 were not performed because
RA also induced a decreased expression ofGAPDH mRNA.
Statistical analysis
The mean and standard errors ofthe mean (s.e.m.) ofthe data were
calculated. Statistical analyses were performed by Student's t-test
for individual and for paired samples.
RESULTS
Effect on susceptibilities of SC-Mi cells to LAK
cytotoxicity by various concentrations of RA
The possible change in susceptibility ofSC-MI cells to LAK cyto-
toxicity as induced by RA was initially determined after SC-Mi
cells were co-cultured with RA at various concentrations for 6
days. As shown in Figure 1, susceptibility ofSC-MI cells to LAK
lysis generated from culturing PBMCs ofhealthy donors with IL-2
was reduced, and the reduction was RA dose dependent at concen-
trations ranging from 0.001-10 ,UM that were examined. A signifi-
cant decrease in LAK cytotoxicity was detected at RA
concentrations of 0.1 gM (P=0.0015) and 10 gIM (P=0.0002). The
RA concentration of5 ,UM was selected for further experiments.
RA at 5 gIM was added to SC-MI culture medium and SC-MI
cells were harvested for LAK cytotoxicity assay after 2, 6 and 10
days of incubation. As shown in Figure 2, the resistance of RA-
treated SC-Mi cells to LAK lysis was time dependent. To ascer-
tain the validity of RA-induced resistance to LAK cytotoxicity,
two additional cancer cell lines, a leukaemia cell line HL-60 and a
hepatic cancercell line Hep 3B, were used as target cells in kinetic
studies. To determine the time required for the development of a
significant RA-induced resistance, tumourcells were cultured with
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Figure 1 The effect of various concentrations of RA, i.e. dose dependent, on
susceptibility of SC-Mi tumour cells to LAK lysis. SC-Mi cells were
incubated with RA at the concentrations indicated for 6 days before being
used as target cells in a cytotoxicity assay. The LAK activity expressed as
lytic units was generated by co-culturing PBMCs of normal donors with 3000
IU ml-' IL-2 for 4 days and was measured by standard 4-h 5'Cr-release
assay. The results are expressed as means + s.e.m. (bars) from triplicate
assays
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Figure 2 The effect of the length of RA treatment on sensitivity of SC-Mi
tumour cells to LAK lysis. Untreated SC-Mi cells * and SC-Mi cells treated
with RA at 5gmM
o for various periods of time in culture were used as target
cells in a LAK cytotoxicity assay. The results are expressed as means ±
s.e.m. (bars) from triplicate assays
RA at 5 gM for 1, 2, 6 and 10 days before testing their sensitivity to
LAK lysis. Figure 3 shows that the RA-induced resistance to LAK
cytotoxicity was also detected in both HL-60 and Hep 3B cell lines.
Although a difference in the sensitivity to LAK lysis was detected
between SC-Mi cells and HL-60 and Hep 3B cells, the kinetics of
resistance development was similar. A significant resistance to
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Figure 3 Induction of resistance by RA to LAK cytotoxicity in gastric (El; SC-
Ml), promyelocytic leukaemia (*; HL-60) and hepatic (M; Hep 3B) cancer
cell lines. Cancer cells were incubated with RA at 5gM for various periods of
time, as indicated, before being used as target cells in a LAK cytotoxicity
assay. The results represent means ± s.e.m. (bars) from triplicate assays
LAK lysis occurred when target cells were cultured with RA for as
little as 2 days in culture and reached a maximum plateau after
culture for 6 days (data from culture ofRA for 10 days not shown).
Cell cycle phase distribution and cyclins analysis
The effect ofRA on the cell cycle phase distribution was analysed
by flow cytometry. As shown in Table 1, treatment of non-
synchronized SC-Ml cells with RA at the concentrations of
0.01 ,UM and 1 ,UM resulted in a significant increase in the fractions
of cells in G0G1 phase (P<0.05 and P<0.01 respectively) and a
significant decrease in the fraction of cells in S phase (P<0.01 at
1 gM RA). Also noted is that the changes were in a RA dose
dependent manner.
Additional experiments were performed to examine the expres-
sion ofcyclin A and cyclin B1 mRNA in SC-Ml cells treated with
RA. Figure 4 shows that a decrease in the expression of cyclin A
mRNA (2.8 and 2.0 kb) and cyclin Bl mRNA (1.7 kb) was
detected in SC-Ml cells after co-culture with RA (5 ,UM) for 96 h,
Table 1 Effect of RA on the cell cycle distribution of SC-Mi cellsa
Percentage of cells in cell cycle phase
Treatments GJG1 S G2/M
SC-Mi 49.4 ± 0.1b 27.7 ± 4.7 22.1 ± 4.5
SC-Mi + RA (0.01 gM) 56.9 ± 2.0* 23.5 ± 4.0 18.4 ± 1.7
SC-Mi + RA (1 gM) 67.8 +2.1 ** 9.4 ±2.1* 21.9 ± 4.5
aAfter culture with RA at the concentrations shown for 6 days, distribution of
cell cycle phase was analysed by flow cytometry. bThe number represents
mean ± s.e.m. of three experiments. *P< 0.05, **P < 0.01, for SC-Mi vs
SC-Mi + RA.
GAPDH 1
Figure 4 Expression of cyclin mRNA in SC-Mi cells treated with RA at 5 gm
for 12 and 96 h. Poly(A)+ RNA (3 gig per lane) was hybridized with
digoxigenin-labelled cDNA for cyclin A and cyclin Bi. Probes were removed
and membranes were rehydridized with a GAPDH probe as shown on the
lower section of each panel
but not at 12 h. Results also show that a significant decrease in
cyclin A and cyclin Bo mRNA was detected after SC-Ml cells
were cultured with RA for 24 h, and that the decrease in cyclins A
and B by RA was in both a dose- and time-dependent manner
(data not shown).
Formation of conjugates between effector LAK and
target tumour cells
To determine the effect of RA treatment on the recognition of
tumour cells by LAK cells, RA-treated and untreated tumour cells
were compared in a direct binding assay in which conjugate
formation between effector LAK cells and target tumour cells,
SC-M and Hep 3B, was examined directly by a microscope. The
treatment of SC-Ml cells and Hep 3B cells with RA at 5 ,UM for
6 days reduced their susceptibilities to lysis by LAK cells as
shown previously (Figure 3), yet no significant difference in the
frequency of LAK cells forming the conjugates with RA-treated
SC-MI cells or Hep 3B cells was discernible (Table 2). The results
suggested that the reduced LAK lysis was not caused by any
decrease in binding or contact between effectors and target cells.
Table 2 Comparison of conjugate formation between effector LAK cells and
target SC-Mi cells and Hep 3B cells with and without treatment with RA
Target cell Conjugate/total target cells (%)
SC-Mi 48.7+ 2.5a,b
SC-Mi + RAc 50.3 ± 0.7
Hep 3B 23.8 + 2.1
Hep 3B + RAc 24.3 ± 1.9
aThe numbers are calculated from counting 200 target cells and are
expressed as mean ± s.e.m. from three experiments. bAll P-values are > 0.05
for SC-Mi vs SC-Mi + RA. cCultured with RA at 5gM for 6 days.
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Northern blot analysis of RAR
Because a significant resistance to LAK in SC-MI cells was detected
after treatment with RA for 2 days, changes in steady-state levels of
RAR mRNA in SC-MI cells treated with RA for 2 days were
analysed. Following exposure to RA for2 days, steady-state levels of
two RARa mRNA transcripts (3.5 and 2.9 kb) were increased in
SC-Mi cells in a RA dose-dependent manner (Figure 5, top). The
4.8-kb band was derived from cross-hybridization with 28S ribo-
somal RNA and was not regulated by RA. No detectable level of
RARP mRNA was observed in SC-M1 cells (Figure 5, middle).
The expression of two RARy mRNA transcripts (3.2 and 3.0 kb)
remained unchanged (Figure 5, bottom).
Table 3 Flow cytometric analysis of the expression of HLA, ICAM and LFA
molecules on SC-Mi cells
Molecules examined SC-Mi SC-Mi + RAa
HLA class 1 100.7 ± 6.2b,c 93.1 + 6.0b,c
HLA class 11 1.5 ± 0.2 1.3± 1.1
ICAM-1 101.6 ± 13.6 101.2 ± 13.9
ICAM-2 0.7+ 0.6 1.3 ± 1.3
LFA-3 70.9 + 7.6 66.4 + 5.0
aThe SC-Mi cells were cultured with RA (5gM) for 6 days. bThe numbers
represent fluorescence intensity and are expressed as mean ± s.e.m. from
five experiments. cAll P-values are >0.05 for SC-Mi vs SC-Mi + RA.
Expression of cell surface and adhesion molecules
Cytotoxicity mediated by LAK cells involves adhesive interac-
tions between LFA-1 (CD 1la/CD 18) and CD 2 on immune effec-
tors and ICAM-1, -2 (CD 54 and CD 102) as well as LFA-3 (CD 58)
on tumour cell targets (Robertson et al, 1990; Foreman et al,
1993). Although LAK lysis is MHC unrestricted, the expression of
MHC molecules may play a regulatory role (De Fries and Golub,
1988). These surface and adhesion molecules and their ligands are
SC-Mi
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Figure 5 Expression of RAR mRNA in SC-Mi cells treated with various
concentrations of RA for 2 days. Poly (A)+ RNA (10 jig per lane) was
hybridized with digoxigenin-labelled cDNA for RARa, RAR, and RARy.
Probes were removed and membranes were rehybridized with 0-actin probe
as shown on the lower section of each panel
not only important in effector to target cell adhesion, but also play
a significant role in effector activation (Galandrini et al, 1992).
Therefore, whether expression of ICAM-1 and -2, LFA-3 and
HLA class I and II molecules were different on SC-Mi cells from
those on RA-treated SC-Mi cells was examined by flow cytom-
etry. As shown in Table 3, SC-MI cells expressed HLA class
I, ICAM-1 and LFA-3, but not HLA class II or ICAM-2 molecules.
These results indicated that the expression ofthese adhesion mole-
cules was similar in SC-Mi tumour cells with and without treat-
ment with RA.
DISCUSSION
Retinoids are becoming increasingly useful therapeutic agents for
some neoplasms, such as premalignant and malignant diseases
affecting the skin, head and neck, lung, bladder, uterine cervix and
bone marrow (Smith et al, 1992). Retinoids are known to exert a
variety ofdirect effects on tumourcells, including the induction of
differentiation and apoptosis (Martin et al, 1990) and the inhibition
of cell proliferation (Lotan et al, 1990). Morphological changes,
alterations in expression of cell surface molecules, notably adhe-
sion molecules, and a number ofmetabolic and enzymatic changes
have been reported (Lotan et al, 1990; Triozzi et al, 1992; Bouillon
and Audette, 1994). Thus, the effects of retinoids on tumour cells
are numerous and any of these retinoid-induced changes, alone or
in combination, may contribute to the reduced sensitivity to LAK-
mediated cytolysis that we have described.
In the present study, we have reported that susceptibility of
gastric cancer, promyelocytic leukaemia and hepatic cancer cell
lines to LAK lysis was greatly reduced by RA. Similarphenomena
of RA-inducible resistance to LAK cytotoxicity have also been
reported. The exposure of HL-60 cells to RA, interferon-a, inter-
feron-5 or interferon-y has produced an increased protection from
LAK cytolysis (Triozzi et al, 1992). Interferon-y has also been
reported to induce protection of a variety of cancer cell lines, e.g.
renal cell cancer, melanoma, sarcoma and lymphoma, from LAK
cytolysis (De Fries and Golub, 1988). Additionally reported is that
phorbol 12-myristate 13-acetate, a differentiation enhancer,
induced melanoma cells to generate resistance to LAK cells, while
undergoing growth inhibition and neuron-like differentiation
(Correale et al, 1992).
Although interferon has been implicated as playing a role, the
exact mechanisms underlying RA-enhanced resistance of cancer
cells to LAK cell activity remain unknown. Any alteration ofcancer
cells, which may interfere with any of the stages of cell-mediated
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cytotoxicity, i.e. recognition, triggering, programming and lysis,
could be responsible for the decreased susceptibility of LAK-
mediated cytotoxicity (Apasov et al, 1993; Henkart, 1994). These
may include a reduction or masking of relevant recognition struc-
tures, a reduced ability to trigger the release of cytotoxic media-
tors, a decrease in transduction of cytotoxic signals and/or an
increase in cellular repairing.
The recognition structures or factors on the target cancer cell
surface that mediate LAK cytolysis remain largely unknown.
Cellular adhesion molecules such as ICAM-1, ICAM-2, LFA-3
and MHC class I and II antigens have been proposed by some
investigators as playing an auxiliary but critical role in the initial
contact between immune effectors and target tumour cells, but the
proposition is not universally accepted (De Fries and Golub, 1988;
Robertson et al, 1990; Correale et al, 1992; Galandini et al, 1992;
Triozzi et al, 1992; Fady et al, 1993; Foreman et al, 1993; Henkart,
1994; Katsanis et al, 1994). In agreement with the majority of
these reports, our results indicate that the expression of ICAM-1,
ICAM-2, LFA-3 and MHC class I and II molecules are not associ-
ated with the RA-induced susceptibility of SC-Mi cells to LAK
lysis. Our other data obtained from direct examination of immune
effector-tumour cells conjugate formation also reveal that the
recognition and contact between cancer cells and effectors are not
involved. We have shown the presence of RARP and RARy
mRNAs and the absence ofRARf mRNA in SC-MI cells (Shyu et
al, 1995). In the present study, we have further demonstrated that
the expression of RARa mRNA in SC-M1 cells was significantly
increased by co-culturing with RA, and that the expression of
RARf and RARy mRNA was not affected. In fact, RAR3 and
RARy mRNA in SC-MI cells remain unchanged throughout the
duration ofco-culturing with RA for a period of2 years (SY Jiang,
unpublished data). It is likely that RARox may be involved in the
altered susceptibility of SC-Mi cells to LAK cell lysis, whereas
RARf and RARy would not play any role. RXRs were not exam-
ined in this study, as we have shown that SC-MI cells express no
RXRa, while the limited amount of RXRx and RXRf expressed
as not correlated with RA sensitivity.
Cellular proliferation follows an orderly progression through
the cell cycle. Of interest to note is that incubation of SC-MI cells
with RA results in an increase inGO/GI phase and a decrease in S
phase, as analysed by cell cycle distribution. Morphologically,
culture with RA produces 'enlarged and flattened' SC-Ml cells
(Shyu et al, 1995). Neither a reduced viability of cells nor
evidence ofapoptosis, such as nuclear fragmentation or chromatin
condensation, has been observed in RA-treated SC-MI cells (Shyu
et al, 1995). Cyclin analysis has revealed that cyclin A and cyclin
B1, the commonly regarded regulators of the transition to mitosis
(Cordon-Cardo, 1995), are greatly reduced. Taken together, these
results suggest that RA exerts a cytostatic effect on SC-Ml cells.
Furthermore, LAK-mediated cytolysis requires an active partici-
pation from the target cells that are to be metabolically active
(Zychlinsky et al, 1991). Therefore, the RA-induced cytostatic
effect in SC-Mi cells may derive from such a mechanism that
eventually results in a reduction ofsensitivity to LAK cytotoxicity
as observed. Similar observations have been reported in breast
cancer cells and leukaemia cells in which susceptiblity to LAK
cytotoxicities increases when target cancer cells become prolifera-
tive in response to the stimulation of oestradiol and granulo-
cyte-monocyte colony-stimulating factor respectively (Albertini
et al, 1992; Teichmann et al, 1992). One report has shown that
LAK cells are able to bind target cells independently of the cell
cycle phase in Chang cell lines as measured by cytometric and
morphological parameters (Nano et al, 1995). However, binding
between LAK cells and their targets is not equal to lysis. Our
results in this study have also demonstrated that the binding
between LAK cells and targets was unchanged by RA modifica-
tion of SC-M1 cells.
In summary, the present study has indicated that culture of
SC-M1 gastric cancer cells with RA has produced a decrease in
their susceptibilities to LAK-mediated cytotoxicity. The prevailing
notions, such as a reduced binding between immune effectors and
target tumour cells, a decreased expression of ICAM and MHC
class I molecules and an alteration of RARf, appear not to be
involved. The underlying mechanism is caused in part by a cyto-
static effect of RA on target tumour cells. The phenomenon seen
applies to a range of cell lines and further study would be advis-
able in those tumours for which retinoic acid therapy and IL-2 are
contemplated.
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